drugset
drugset / Trial / NCT04920903

A Single and Multiple Ascending Dose Study of COR588

NCT04920903 ↗

Phase 1 Completed 64 enrolled Cortexyme Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety and tolerability of COR588 HCl in healthy male and female subjects.

Timeline

Start
2021-08-26
Primary completion
2022-04-30
Completion
2022-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject COR588 Unknown — Oral

Indications

No indication recorded.